Pregabalin Capsule
Product Images NDC 80425-0327

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 80425-0327). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Advanced Rx Pharmacy Of Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Fig 1 (Figure 1)

A line graph depicting percent improvement in pain from baseline (x-axis) versus the percent of patients improved (y-axis). Four curves represent different treatments: Pregabalin 200 mg three times a day, 100 mg three times a day, 25 mg three times a day, and placebo. The data illustrate varying levels of pain improvement among these groups.*

FDA Label Image

Fig 10 (Figure 10)

A line graph comparing the estimated percentage of subjects without LTR over 180 days between Pregabalin and placebo groups. The y-axis shows the estimated percentage from 0% to 100%, and the x-axis shows time in days from 0 to 180. The Pregabalin group is represented by a solid line, while the placebo group is shown with a dashed line.*

FDA Label Image

Fig 11 (Figure 11)

A line graph comparing the percent of subjects improved from baseline to Week 12 using the BOCF method for Pregabalin versus Placebo. The x-axis shows percent improved from 0 to 100, and the y-axis shows percent of subjects improved from 0 to 100. Two lines are plotted: a solid line representing Pregabalin and a dashed line representing Placebo, with Pregabalin consistently showing higher improvement percentages.*

FDA Label Image

Fig. 12 (Figure 12)

A line graph comparing the percent of subjects improved for Pregabalin versus placebo treatments. The X-axis shows the percent improved from baseline to week 16 BOCF, ranging from 0 to 100. The Y-axis indicates the percent of subjects improved, from 0 to 100%. Two lines represent Pregabalin (solid) and placebo (dashed), showing higher improvement percentages for Pregabalin.*

FDA Label Image

Fig 2 (Figure 2)

A line chart showing the percent of patients improved versus percent improvement in pain from baseline, comparing Pregabalin 100 mg three times a day with placebo. The vertical axis measures percent of patients improved, and the horizontal axis shows percent improvement in pain from baseline.*

FDA Label Image

Fig 3 (Figure 3)

A line graph showing the percent of patients improved plotted against percent improvement in pain from baseline. The graph includes data lines for Pregabalin dosed at 75 mg, 150 mg, and 300 mg twice a day, as well as a placebo group, indicating comparative patient improvement efficacy across different doses.*

FDA Label Image

Fig 4 (Figure 4)

A line graph showing the percent of patients improved versus percent improvement in pain from baseline. It compares three groups: Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, and placebo, with Pregabalin 200 mg showing the highest improvement rates and placebo the lowest.*

FDA Label Image

Fig 5 (Figure 5)

A line graph showing the percent of patients improved versus percent improvement in pain from baseline for Pregabalin 100 mg three times a day, Pregabalin 50 mg three times a day, and placebo groups. The graph compares the pain improvement distributions across these treatments.*

FDA Label Image

Fig 6 (Figure 6)

A bar chart comparing responder rates (%) in two studies, Study E1 and Study E3, for placebo and various dosages of pregabalin. Study E1 shows increasing responder rates from placebo to 600 mg/day doses with BID dosing. Study E3 compares placebo, 300 mg/day BID, and 600 mg/day TID dosages, showing higher responder rates with pregabalin doses. Statistically significant differences versus placebo are indicated.*

FDA Label Image

Fig 7 (Figure 7)

A line graph depicting median percent change in seizure reduction from baseline versus dose in mg/day. The graph includes data points for four different studies labeled E1 BD, E2 TID, E3 BD, and E3 TID, each represented by distinct symbols. Significant p-values are noted next to relevant data points.*

FDA Label Image

Fig 9 (Figure 9)

A line graph showing the percent of patients improved versus percent improvement in pain from baseline. It compares Pregabalin at doses of 800 mg, 450 mg, and 300 mg daily against placebo, with Pregabalin 800 mg showing the highest percentage of patient improvement. The x-axis represents percent improvement in pain, while the y-axis shows the percent of patients improved.*

FDA Label Image

Label 1 (Pregabalin 50mg 80425 0327 01)

Packaging label for Pregabalin 50 mg capsules, in a pack of 30, labeled by Advanced Rx Pharmacy of Tennessee, LLC, Nashville, TN. The label includes storage instructions (20°-25°C), a comparison to Lyrica, NDC 80425-0327-01, and expiration date 4/20/2023. The label also shows lot number and manufacturer Sciegen Pharmac with an NDC starting 00000.*

FDA Label Image

Label 2 (Pregabalin 50mg 80425 0327 02)

Pregabalin 50 mg capsule packaging label from Advanced Rx Pharmacy of Tennessee, LLC. The label includes storage instructions (20°-25°C), a QR code, and references to the product's NDC 80425-0327-02 and source NDC 50228-0351-90. The label indicates a Schedule V controlled substance and an expiration date of 4/20/2023.*

FDA Label Image

Label 3 (Pregabalin 50mg 80425 0327 03)

Packaging label for Pregabalin 50 mg capsules, an oral prescription drug. The label shows the product name, strength, capsule form, and includes storage instructions at 20-25°C (68-77°F). It is labeled by Advanced Rx Pharmacy of Tennessee, LLC, with a reference to compare to LYRICA and includes lot and expiration details.*

FDA Label Image

Structure (Structure)

Chemical structure of Pregabalin, showing the molecular arrangement including carboxyl (CO2H) and amino (NH2) functional groups in the compound.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.